IL6 and osteosarcoma: Combined use of TGF-β inhibitors and IL-6 blockers can reduce drug resistance and prevent the progression of osteosarcoma, which is based on the finding that EVs carry functional TGF-β molecules and elevate IL-6 production, promoting OS growth and metastasis 65.